2. Search Result
Search Result
Results for "

human Tregs

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

1

Biochemical Assay Reagents

15

Inhibitory Antibodies

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99014
    Cusatuzumab
    1 Publications Verification

    ARGX-110

    		 Fc Receptor (FcR) NF-κB Inflammation/Immunology Cancer
    Cusatuzumab (ARGX-110) is a selective competitive blocker targeting CD70 (with an equilibrium dissociation constant of 17 pM for binding to human CD70). Cusatuzumab also possesses enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. It is a humanized IgG1 monoclonal antibody, artificially synthesized through humanization and genetic engineering modifications (CH2 region mutation to enhance effector function). Cusatuzumab has a dual mechanism of action: firstly, it competitively blocks the interaction between CD70 and CD27, inhibiting the CD27-NF-κB signaling pathway, reducing regulatory T cell (Treg) activation and tumor cell proliferation; secondly, by enhancing binding to FcγRIIIa, it mediates ADCC and antibody-dependent cellular phagocytosis (ADCP), directly lysing CD70-positive tumor cells. Cusatuzumab can efficiently eliminate leukemia stem cells (LSCs), induce tumor cell differentiation and apoptosis, restore immune surveillance, and target CD70-positive tumors. Cusatuzumab is used in the study of acute myeloid leukemia (AML) .
    Cusatuzumab
  • HY-P99728
    Melredableukin alfa

    RG7835; RO7049665

    		 Interleukin Related Metabolic Disease Inflammation/Immunology
    Melredableukin alfa (RG7835) is a bivalent conjugate composed of a human IL-2 mutant (T3A, N88D, C125A) and human IgG1. Melredableukin alfa exhibits enhanced Treg cell selectivity in cynomolgus monkey and humanized mouse models. Melredableukin alfa can be used in research related to ulcerative colitis and autoimmune hepatitis .
    Melredableukin alfa
  • HY-113238A
    Lithocholic acid 3-sulfate disodium

    Sulfolithocholic acid disodium; LCAS disodium

    		 GPR39 ROR Metabolic Disease Inflammation/Immunology
    Lithocholic acid 3-sulfate disodium is a GPR39 agonist, with EC50 values of 41 μM and 42.4 μM in M39-20 and hGPR39-2 cells, respectively, in the absence of Zn 2+, and 0.88 μM and 0.97 μM in the presence of Zn 2+. Lithocholic acid 3-sulfate disodium acts as a RORγt ligand. Lithocholic acid 3-sulfate disodium stimulates the GPR39 receptor to initiate intracellular calcium signaling, independent of the Zn 2+-binding sites H17 and H19. LCA-3-S selectively inhibits Th17 cell differentiation by targeting RORγt. Lithocholic acid 3-sulfate disodium can be used in the research of cholestatic liver diseases .
    Lithocholic acid 3-sulfate disodium
  • HY-P991180
    TRX-518

    		TNF Receptor Cancer
    TRX-518 is a humanized agylcosyl IgG1 anti-GITR mAb, , and is a GITR agonist. TRX-518 binds to the extracellular domain of human GITR, abrogates Treg-mediated suppression. TRX-518 increases effector T cell activation and pro-inflammatory cytokine production, reduces circulating and intratumor Treg frequencies. TRX-518 destabilizes Treg phenotype via Foxp3 downregulation and T-bet upregulation. TRX-518 can be used for the research of solid tumors[1][2][3].
    TRX-518
  • HY-P990914
    Denikitug

    GS-1811; JTX-1811

    		 CCR Inflammation/Immunology Cancer
    Denikitug (GS-1811; JTX-1811) is a humanized monoclonal antibody against CCR8 receptor with a KD of 16.8 pM. Denikitug specifically binds to human CCR8, inhibits CCL1-induced downstream CCR8 signaling. Denikitug selectively depletes cells expressing CCR8 via antibody-dependent cellular cytotoxicity (ADCC). Denikitug promotes anti-tumor immunity and can be used for the research of cancer and immunology .
    Denikitug
  • HY-159692
    AZD8701

    IONIS-1063734

    		 TGF-beta/Smad Inflammation/Immunology Cancer
    AZD8701 (IONIS-1063734) is an antisense oligonucleotide targeting FOXP3 in regulatory T cells (Tregs), with a human IC50 of 65.2 nM. AZD8701 binds to intronic sites of all FOXP3 pre-mRNA isoforms and mediates dose-dependent FOXP3 knockdown via free uptake. AZD8701 can be used in cancer-related research .
    AZD8701
  • HY-P991179
    MK-4166

    		TNF Receptor Cancer
    MK-4166 is a humanized IgG1 agonist monoclonal antibody targeting GITR. MK-4166 enhances the proliferation of both naïve and tumor-infiltrating T lymphocytes .
    MK-4166
  • HY-P991192
    BI-1808

    		TNF Receptor Cancer
    BI-1808 is a human IgG1 monoclonal antibody that targets TNFR2by blocking interaction of TNFR2 with ligand TNF-α, confers FcγR-dependent depletion of Treg and mediates expansion of intratumoral CD8 + T cells .
    BI-1808
  • HY-P990703
    Porustobart

    HBM-4003

    		 CTLA-4 Inflammation/Immunology
    Porustobart (HBM-4003) is a fully human anti-CTLA-4 heavy chain only antibody (HCAb). Porustobart can significantly improve the depletion of regulatory T cells (Treg cells) with high CTLA-4 expression in tumor tissues by enhancing ADCC activity. Porustobart can be used for tumor research .
    Porustobart
  • HY-P990031
    Dargistotug

    M-6223

    		 Transmembrane Glycoprotein Inflammation/Immunology Cancer
    Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody targeting TIGIT (T cell immune receptor with Ig domain and ITIM). TIGIT is an inhibitory immune checkpoint that promotes NK cell depletion and reduces the secretion of cytokines by binding to CD155 and other antibodies. It can also directly or indirectly inhibit effector T cells and upregulate Tregs cells, thereby exerting immunosuppression. Function .
    Dargistotug
  • HY-P990868
    Anti-CD2 Antibody (CB.219)

    		CD2 Inflammation/Immunology Cancer
    Anti-CD2 Antibody (CB.219) is an anti-human CD2 IgG2b monoclonal antibody. Anti-CD2 Antibody (CB.219) can reduce the infiltration of T cells, macrophages, and the number of Tregs in the colon. Anti-CD2 Antibody (CB.219) can be used for research on infection and inflammation such as toxoplasma infection and colitis. The recommend isotype control of Anti-CD2 Antibody (CB.219): Mouse IgG2b kappa, Isotype Control (HY-P99982) .
    Anti-CD2 Antibody (CB.219)
  • HY-174611
    Human IL2RA mRNA

    		mRNA Inflammation/Immunology
    Human IL2RA mRNA encodes the human interleukin 2 receptor subunit alpha (IL2RA) protein, a receptor for interleukin-2. IL2RA is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity.
    Human IL2RA mRNA
  • HY-P991403
    BC011

    		TNF Receptor Cancer
    BC011 is a human monoclonal antibody (mAb) targeting TNFRSF1B. BC011 promotes CD8+T cell proliferation and depletes Treg cells, thereby increasing the proportion of effector T cells in the tumor microenvironment. BC011 can be used in tumor Immunity research.
    BC011
  • HY-P99911
    Efizonerimod alfa

    MEDI-6383

    		 Orexin Receptor (OX Receptor) Inflammation/Immunology Cancer
    Efizonerimod alfa (MEDI-6383) is a recombinant human OX40L IgG4P Fc fusion protein that assembles into a hexameric structure and exerts potent agonist activity upon binding to OX40. The activity of Efizonerimod alfa is enhanced by Fcγ receptor-mediated aggregation. Efizonerimod alfa binds to OX40 on the surface of activated T cells, induces NF-κB promoter activity in OX40-expressing T cells, and triggers the production of Th1-type cytokines, T cell proliferation, and resistance to regulatory T cell (Treg)-mediated suppression. Efizonerimod alfa enhances the cytolytic activity of tumor-reactive T cells and slows tumor growth in immunodeficient mice. Efizonerimod alfa induces the proliferation of CD4, CD8, and B cells in the peripheral blood of healthy non-human primates. Efizonerimod alfa can be used in the research of advanced solid malignancies and melanoma .
    Efizonerimod alfa
  • HY-P991942
    Lanerkitug

    BAY3375968; TPP-23411

    		 CCR Inflammation/Immunology Cancer
    Lanerkitug (BAY3375968) is a fully human monoclonal IgG1 anti-human CCR8 antibody. Lanerkitug selectively depletes human CCR8 + Tregs via antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). Lanerkitug can be used in the research of solid tumors .
    Lanerkitug
  • HY-P991942A
    Lanerkitug (FUT8-KO)

    BAY3375968 (FUT8-KO); TPP-23411 (FUT8-KO)

    		 CCR Cancer
    Lanerkitug (FUT8-KO) (BAY3375968 (FUT8-KO)) is an anti-CCR8 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Lanerkitug (HY-P991942) selectively depletes human CCR8+Tregs via antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). Lanerkitug can be used in the research of solid tumors .
    Lanerkitug (FUT8-KO)
  • HY-P992365
    HFB101110

    		CCR Cancer
    HFB101110 is a human-derived inhibitor and Treg depleter that specifically targets CCR8. It does not bind to the homologous CCR4 receptor and is mainly used in research on solid tumors, renal cell carcinoma and colorectal cancer. HFB101110 blocks hCCL1 binding by interacting with the N-terminal extracellular domain of hCCR8, thereby inhibiting hCCL1-induced calcium influx, chemotaxis and downstream signaling pathways. Meanwhile, HFB101110 can mediate ADCC effects to specifically deplete CCR8-positive cells, including intratumoral Tregs. HFB101110 exhibits favorable anti-tumor activity and pharmacokinetic properties .
    HFB101110
  • HY-122081
    CPI-644

    		Histone Acetyltransferase LAG-3 CTLA-4 PD-1/PD-L1 Cancer
    CPI-644 is a selective EP300/CBP bromodomain inhibitor, with an IC50 of 0.18 µM against the CBP bromodomain. CPI-644 reduces the proportion of FOXP3 + cells and downregulates the expression of LAG-3, CTLA-4 and PD-1. CPI-644 can be used in cancer-related research .
    CPI-644

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: